ファーマコゲノミクス技術の世界市場

ファーマコゲノミクス技術の世界市場は2030年までに114億米ドルに到達

2024年に71億米ドルと推定されるファーマコゲノミクス技術の世界市場は、2024年から2030年にかけてCAGR 8.2％で成長し、2030年には114億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるオンコロジーは、CAGR 9.4%を記録し、分析期間終了時には53億米ドルに達すると予測されます。神経疾患分野の成長率は、分析期間中CAGR 8.9％と推定されます。

米国市場は19億米ドルと推定、中国はCAGR 12.9％で成長予測

米国のファーマコゲノミクス技術市場は2024年に19億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに25億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.1%と7.9%と予測されています。欧州では、ドイツがCAGR 5.4%で成長すると予測されています。

ファーマコゲノミクス技術市場、主要動向と促進要因のまとめ

ファーマコゲノミクスは医薬品開発と個別化医療をどう変えるか？

ファーマコゲノミクス技術は、個人の遺伝子構成に基づいた個別化医療を可能にすることで、製薬業界に革命をもたらしています。遺伝子の変異が薬物反応にどのように影響するかを研究することで、ファーマコゲノミクスは標的療法の開発、薬物投与量の最適化、副作用の軽減を可能にします。画一的なアプローチから精密医療へのシフトは、治療効果を高め、試行錯誤の処方を最小限に抑え、患者の転帰を大幅に改善します。

米国食品医薬品局（FDA）、欧州医薬品庁（EMA）、国際整合性評議会（ICH）などの規制機関は、医薬品の承認、表示、市販後調査において、薬理遺伝学をますます認めつつあります。多くの製薬企業は、バイオマーカーの同定、患者集団の層別化、医薬品開発期間の短縮を目的として、臨床試験に薬理ゲノムデータを統合しています。次世代シークエンシング（NGS）、CRISPRベースの遺伝子編集、人工知能（AI）を活用した遺伝子解析の急速な進歩により、薬理ゲノム学は精密医療の礎石となる準備が整っています。

ファーマコゲノミクス技術の成長を促進する主な動向とは？

ファーマコゲノミクスの分野は、ゲノムシーケンス、バイオインフォマティクス、AIを活用した創薬の飛躍的進歩により、急速に進化しています。最も重要な動向の1つは、全ゲノムシーケンス（WGS）および次世代シーケンス（NGS）の広範な採用であり、これにより薬物代謝に関連する遺伝子変異を迅速かつコスト効率よく同定できるようになりました。シーケンシング技術の低コスト化に伴い、ファーマコゲノミクス検査は臨床応用や集団シーケンシング研究にとってより利用しやすくなっています。

もう一つの重要な動向は、ファーマコゲノミクス調査におけるAIと機械学習（ML）の統合です。AIを活用したアルゴリズムは、膨大な遺伝子データを解析して薬剤と遺伝子の相互作用を特定し、治療反応を予測し、個別化された薬剤レジメンを開発することができます。また、AIを活用した創薬プラットフォームは、新規バイオマーカーや治療標的の同定を加速し、従来の医薬品開発に伴う時間とコストを削減しています。

DTC（ダイレクト・トゥ・コンシューマー）薬理ゲノミクス検査の台頭は、もう一つの変革的動向です。23andMeやColor Genomicsのような企業は、消費者に薬物代謝や潜在的な薬物有害反応に関する洞察を提供する遺伝子検査キットを提供しています。規制当局による監視は依然として課題であるが、消費者主導のヘルスケアに対する需要の高まりがこの市場の成長を後押ししています。

さらに、CRISPRに基づく遺伝子編集と遺伝子治療の進歩は、薬理ゲノミクスの範囲を診断にとどまらず治療応用へと拡大しつつあります。遺伝子編集技術は、オーダーメイドの医薬品開発、標的がん治療、希少疾患治療を可能にし、薬理ゲノミクス主導の精密医療の需要をさらに押し上げています。

最終用途はファーマコゲノミクス市場をどのように形成しているか？

ファーマコゲノミクス技術は、腫瘍学、心臓病学、精神医学、神経学、感染症を含む複数の治療分野に影響を与えています。各分野は独自の方法でファーマコゲノミクスの恩恵を受け、薬剤選択や治療戦略を最適化しています。

腫瘍学は、薬理ゲノミクスが影響を及ぼしている最も重要な分野の一つです。乳がんのHER2阻害剤（トラスツズマブ）や肺がんのEGFR阻害剤（ゲフィチニブ）などの標的がん治療は、遺伝子プロファイリングに基づいています。ファーマコゲノミクス検査は、どの患者が特定の治療から最も恩恵を受けるかを腫瘍医が判断し、毒性を軽減し、生存率を改善するのに役立ちます。遺伝子検査と特定の抗がん剤を組み合わせるコンパニオン診断薬の台頭が、この分野の成長をさらに促進しています。

心臓病学では、薬理ゲノミクスが高血圧、抗凝固、コレステロール管理の治療を調整するために利用されています。遺伝子検査は、患者がクロピドグレル（プラビックス）、ワルファリン、スタチンをどのように代謝するかを予測し、最も効果的で安全な投与量を確保することができます。これにより、副作用（ADR）や血栓性合併症のリスクが減少し、心血管疾患管理が改善されます。

精神医学と神経学もまた、薬理ゲノミクスによって大きな進歩を遂げています。抗うつ薬、抗精神病薬、てんかん治療薬は、しばしば患者の反応性に高いばらつきが見られます。遺伝子検査は、SSRI、リチウム、カルバマゼピンなどの薬物がどのように代謝されるかを予測するのに役立ち、治療抵抗性や副作用を減らすことができます。ファーマコゲノミクスはまた、アルツハイマー病やパーキンソン病の調査にも役立っており、遺伝的危険因子に基づく潜在的な治療標的の特定に役立っています。

感染症分野では、ファーマコゲノミクスは抗ウイルス療法、抗生物質耐性研究、ワクチン開発に応用されています。例えば、遺伝子検査は、アバカビルのようなHIV治療（HLA-B*5701スクリーニング）やC型肝炎治療に対する患者の反応を決定し、抗ウイルス効果を向上させ、過敏反応を減少させることができます。

さらに、ファーマコゲノミクスは希少疾患治療薬の開発や希少疾病用医薬品の承認において重要な役割を果たしています。多くの遺伝性疾患は高度な標的治療を必要としており、薬理ゲノミクスは嚢胞性線維症、鎌状赤血球症、デュシェンヌ型筋ジストロフィーなどの疾患に対する遺伝子ベースの治療戦略の同定を可能にしています。

ファーマコゲノミクス技術市場の成長を促進する要因は？

ファーマコゲノミクス技術市場の成長は、ゲノムシークエンシングの進歩、個別化医療に対する需要の増加、規制当局のサポート、医薬品開発におけるアプリケーションの拡大など、いくつかの要因によって牽引されています。医療が精密医療へとシフトする中、製薬会社、研究機関、ヘルスケアプロバイダーは遺伝子検査、バイオインフォマティクスプラットフォーム、AI主導の創薬ツールに多額の投資を行っています。

主な成長要因の1つは、遺伝子配列決定のコストが低下していることです。全ゲノムシーケンスのコストは大幅に下がり、薬理ゲノミクス検査がより身近で費用対効果の高いものとなっています。その結果、医療提供者は遺伝子プロファイリングを日常臨床に取り入れ、ファーマコゲノミクスに基づく診断薬や治療薬の市場を拡大しています。

規制当局もまた、ファーマコゲノミクスの推進に重要な役割を果たしています。FDAは300を超える医薬品にファーマコゲノミクス表示を行い、薬物の代謝や有効性に影響を与える遺伝子マーカーを強調しています。さらに、All of Us Research Program（米国）やUK Biobank Project（英国バイオバンク計画）のようなイニシアチブが、薬理ゲノミクス研究を推進するための大規模な遺伝子データの収集を進めており、この技術のさらなる普及に拍車をかけています。

慢性疾患、がん、薬剤耐性感染症の蔓延も、薬理ゲノミクス・ソリューションの需要を押し上げています。従来の治療アプローチでは、薬物反応や副作用にばらつきが生じることが多いため、薬理ゲノミクスは精密処方や個別化治療戦略を可能にすることで解決策を提供します。さらに、製薬会社は臨床試験を最適化し、医薬品開発を加速するために薬理ゲノミクスを活用しています。遺伝子プロファイルに基づいて患者集団を層別化することで、企業は臨床試験の成功率を向上させ、医薬品開発コストを削減し、治療薬をより早く市場に投入することができます。コンパニオン診断薬やバイオマーカー主導の医薬品承認が台頭してきたことで、薬理ゲノミクスと医薬品イノベーションの結びつきはさらに強まっています。

さらに、政府からの資金援助と官民パートナーシップが、研究と商業化の努力を後押ししています。米国国立衛生研究所（NIH）、欧州医薬品庁（EMA）、日本医療研究開発機構（AMED）などの組織が薬理ゲノミクス研究に投資しており、遺伝子に基づく治療法の開発や集団全体の遺伝子スクリーニングの取り組みにおいて画期的な進歩を可能にしています。ファーマコゲノミクスがAI、ビッグデータ、精密創薬と統合され続けるにつれて、この分野は飛躍的な成長を遂げ、医薬品の開発、処方、モニタリングの方法を変革する態勢が整っています。遺伝子配列決定、バイオマーカー同定、AI主導型解析の進歩により、薬理ゲノム学は個別化医療と高精度ヘルスケアの未来を形作る上でますます中心的な役割を果たすようになるでしょう。

セグメント

治療領域（オンコロジー、神経疾患、心血管疾患、免疫疾患、感染症）;テクノロジー（PCR、インサイチュハイブリダイゼーション、免疫組織化学、シーケンシング、その他）

調査対象企業の例

• 23andMe, Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Coriell Life Sciences
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Genomind, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• Pacific Biosciences of California, Inc.
• Pathway Genomics Corporation
• PerkinElmer, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Wellness Labs

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Pharmacogenomics Technology Market to Reach US$11.4 Billion by 2030

The global market for Pharmacogenomics Technology estimated at US$7.1 Billion in the year 2024, is expected to reach US$11.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the Neurological Disorders segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 12.9% CAGR

The Pharmacogenomics Technology market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

Pharmacogenomics Technology Market: Key Trends & Drivers Summarized

How Is Pharmacogenomics Transforming Drug Development and Personalized Medicine?

Pharmacogenomics technology is revolutionizing the pharmaceutical industry by enabling personalized medicine based on an individual’s genetic makeup. By studying how genetic variations influence drug response, pharmacogenomics allows for the development of targeted therapies, optimized drug dosages, and reduced adverse reactions. This shift from a one-size-fits-all approach to precision medicine enhances treatment efficacy and minimizes trial-and-error prescribing, significantly improving patient outcomes.

Regulatory agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the International Council for Harmonisation (ICH) are increasingly recognizing pharmacogenomics in drug approvals, labeling, and post-market surveillance. Many pharmaceutical companies are integrating pharmacogenomic data into clinical trials to identify biomarkers, stratify patient populations, and accelerate drug development timelines. With the rapid advancement of next-generation sequencing (NGS), CRISPR-based gene editing, and artificial intelligence (AI)-powered genetic analysis, pharmacogenomics is poised to become a cornerstone of precision medicine.

What Are the Key Trends Driving the Growth of Pharmacogenomics Technology?

The field of pharmacogenomics is evolving rapidly, driven by breakthroughs in genomic sequencing, bioinformatics, and AI-driven drug discovery. One of the most significant trends is the widespread adoption of whole-genome sequencing (WGS) and next-generation sequencing (NGS), which enable rapid and cost-effective identification of genetic variants linked to drug metabolism. With the decreasing cost of sequencing technologies, pharmacogenomics testing is becoming more accessible for clinical applications and population-wide studies.

Another key trend is the integration of AI and machine learning (ML) in pharmacogenomics research. AI-powered algorithms can analyze vast amounts of genetic data to identify drug-gene interactions, predict treatment responses, and develop personalized drug regimens. AI-driven drug discovery platforms are also accelerating the identification of novel biomarkers and therapeutic targets, reducing the time and cost associated with traditional drug development.

The rise of direct-to-consumer (DTC) pharmacogenomics testing is another transformative trend. Companies like 23andMe and Color Genomics are offering genetic testing kits that provide consumers with insights into their drug metabolism and potential adverse drug reactions. While regulatory oversight remains a challenge, the increasing demand for consumer-driven healthcare is fueling the growth of this market.

Furthermore, CRISPR-based gene editing and gene therapy advancements are expanding the scope of pharmacogenomics beyond diagnostics into therapeutic applications. Gene-editing technologies are enabling customized drug development, targeted cancer therapies, and rare disease treatments, further propelling the demand for pharmacogenomics-driven precision medicine.

How Are End-Use Applications Shaping the Pharmacogenomics Market?

Pharmacogenomics technology is influencing multiple therapeutic areas, including oncology, cardiology, psychiatry, neurology, and infectious diseases. Each segment benefits from pharmacogenomics in unique ways, optimizing drug selection and treatment strategies.

Oncology is one of the most significant areas where pharmacogenomics is making an impact. Targeted cancer therapies such as HER2 inhibitors for breast cancer (trastuzumab) and EGFR inhibitors for lung cancer (gefitinib) are based on genetic profiling. Pharmacogenomic testing helps oncologists determine which patients will benefit most from specific treatments, reducing toxicity and improving survival rates. The rise of companion diagnostics, which pair genetic testing with specific cancer drugs, is further driving growth in this sector.

In cardiology, pharmacogenomics is being used to tailor treatments for hypertension, anticoagulation, and cholesterol management. Genetic testing can predict how patients metabolize clopidogrel (Plavix), warfarin, and statins, ensuring that they receive the most effective and safest dosage. This reduces the risk of adverse drug reactions (ADRs) and thrombotic complications, improving cardiovascular disease management.

Psychiatry and neurology are also experiencing significant advancements due to pharmacogenomics. Antidepressants, antipsychotics, and epilepsy medications often exhibit high variability in patient response. Genetic testing helps predict how individuals metabolize drugs such as SSRIs, lithium, and carbamazepine, reducing treatment resistance and side effects. Pharmacogenomics is also playing a role in Alzheimer’s and Parkinson’s disease research, helping to identify potential therapeutic targets based on genetic risk factors.

In the infectious disease sector, pharmacogenomics is being applied to antiviral therapies, antibiotic resistance studies, and vaccine development. For example, genetic testing can determine how patients respond to HIV treatments like abacavir (HLA-B*5701 screening) or hepatitis C therapies, improving antiviral efficacy and reducing hypersensitivity reactions.

Additionally, pharmacogenomics is playing a crucial role in rare disease drug development and orphan drug approvals. Many genetic disorders require highly targeted therapies, and pharmacogenomics is enabling the identification of gene-based treatment strategies for conditions like cystic fibrosis, sickle cell disease, and Duchenne muscular dystrophy.

What Factors Are Driving the Growth of the Pharmacogenomics Technology Market?

The growth in the pharmacogenomics technology market is driven by several factors, including advancements in genomic sequencing, increasing demand for personalized medicine, regulatory support, and expanding applications in drug development. As healthcare shifts toward precision medicine, pharmaceutical companies, research institutions, and healthcare providers are investing heavily in genetic testing, bioinformatics platforms, and AI-driven drug discovery tools.

One of the primary growth drivers is the decreasing cost of genetic sequencing. The cost of whole-genome sequencing has dropped significantly, making pharmacogenomics testing more accessible and cost-effective. As a result, healthcare providers are incorporating genetic profiling into routine clinical practice, expanding the market for pharmacogenomics-based diagnostics and therapeutics.

Regulatory agencies are also playing a key role in promoting pharmacogenomics. The FDA has issued pharmacogenomic labeling for over 300 drugs, highlighting genetic markers that influence drug metabolism and efficacy. Additionally, initiatives such as the All of Us Research Program (U.S.) and the UK Biobank Project are collecting large-scale genetic data to advance pharmacogenomics research, fueling further adoption of the technology.

The increasing prevalence of chronic diseases, cancer, and drug-resistant infections is also driving demand for pharmacogenomics solutions. As traditional treatment approaches often result in variable drug responses and adverse reactions, pharmacogenomics provides a solution by enabling precision prescribing and individualized treatment strategies. Furthermore, pharmaceutical companies are leveraging pharmacogenomics to optimize clinical trials and accelerate drug development. By stratifying patient populations based on genetic profiles, companies can improve trial success rates, reduce drug development costs, and bring therapies to market faster. The rise of companion diagnostics and biomarker-driven drug approvals is further strengthening the link between pharmacogenomics and pharmaceutical innovation.

Additionally, government funding and public-private partnerships are fueling research and commercialization efforts. Organizations such as the National Institutes of Health (NIH), the European Medicines Agency (EMA), and the Japan Agency for Medical Research and Development (AMED) are investing in pharmacogenomics research, enabling breakthroughs in gene-based therapy development and population-wide genetic screening initiatives. As pharmacogenomics continues to integrate with AI, big data, and precision drug discovery, the field is poised for exponential growth, transforming the way drugs are developed, prescribed, and monitored. With advancements in gene sequencing, biomarker identification, and AI-driven analysis, pharmacogenomics will play an increasingly central role in shaping the future of personalized medicine and precision healthcare.

SCOPE OF STUDY:

The report analyzes the Pharmacogenomics Technology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Area (Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders, Infectious Diseases); Technology (PCR, In-situ Hybridization, Immunohistochemistry, Sequencing, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• 23andMe, Inc.
• Abbott Laboratories
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• bioMerieux S.A.
• Bio-Rad Laboratories, Inc.
• Coriell Life Sciences
• Eurofins Scientific
• F. Hoffmann-La Roche Ltd
• Genomind, Inc.
• Guardant Health, Inc.
• Illumina, Inc.
• Merck KGaA
• Myriad Genetics, Inc.
• Pacific Biosciences of California, Inc.
• Pathway Genomics Corporation
• PerkinElmer, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Wellness Labs

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Pharmacogenomics Technology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Personalized Medicine Drives Adoption of Pharmacogenomics in Drug Development and Clinical Practice
  • Expansion of Precision Oncology and Targeted Therapeutics Strengthens Business Case for Pharmacogenomic Testing
  • Increasing FDA and EMA Support for Companion Diagnostics Accelerates Integration of Pharmacogenomics into Drug Labeling
  • Technological Advancements in Next-Generation Sequencing (NGS) and Microarray Platforms Enhance Genotyping Efficiency
  • Growing Pipeline of Biomarker-Driven Therapies Spurs Demand for High-Throughput Pharmacogenomics Solutions
  • Expansion of Pharmacogenomics Panels Beyond Oncology Supports Broader Application in Cardiology, Psychiatry, and Pain Management
  • Integration of AI and Bioinformatics in Genomic Data Interpretation Strengthens Clinical Utility and Decision Support
  • Rising Adoption of Pharmacogenomic Testing in Primary Care and Retail Clinics Expands Market Accessibility
  • Value-Based Healthcare and Outcome-Driven Models Promote Reimbursement for Pharmacogenomics-Guided Therapy
  • Growth in Direct-to-Consumer Genetic Testing Encourages Awareness and Uptake of Pharmacogenomics in Wellness and Preventive Care
  • Increased Regulatory Emphasis on Drug Safety and Adverse Event Reduction Drives Investment in Genomic Risk Screening
  • Integration of Pharmacogenomic Data into Electronic Health Records (EHRs) Enhances Workflow and Clinical Adoption
  • Expansion of Clinical Trials Incorporating Genotype Stratification Supports Personalized Drug Response Analysis
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pharmacogenomics Technology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Pharmacogenomics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Neurological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Neurological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Cardiovascular Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Cardiovascular Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunological Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunological Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for PCR by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for PCR by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for In-situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for In-situ Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for In-situ Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Immunohistochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Immunohistochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• JAPAN
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Japan 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• CHINA
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 53: China Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: China 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 56: China Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: China Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: China 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• EUROPE
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Pharmacogenomics Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Europe 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Europe 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 65: Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Europe Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Europe 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• FRANCE
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 68: France Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: France 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 71: France Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: France Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: France 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• GERMANY
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Germany 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 77: Germany Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Germany Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Germany 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Italy 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 83: Italy Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Italy Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Italy 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 86: UK Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: UK 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 89: UK Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: UK Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: UK 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Spain 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 95: Spain Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Spain Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Spain 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Russia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 101: Russia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Russia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Russia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Rest of Europe Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Rest of Europe 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Pharmacogenomics Technology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Asia-Pacific Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Australia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 122: Australia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Australia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Australia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• INDIA
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 125: India Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: India 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 128: India Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: India Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: India 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: South Korea 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 134: South Korea Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: South Korea Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: South Korea 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Asia-Pacific Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Asia-Pacific 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Pharmacogenomics Technology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Latin America 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Latin America 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 149: Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Latin America Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Latin America 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Argentina 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 155: Argentina Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Argentina Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Argentina 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Brazil 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 161: Brazil Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Brazil Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Brazil 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Mexico 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 167: Mexico Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Mexico Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Mexico 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Latin America Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Latin America Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Latin America 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Pharmacogenomics Technology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Middle East 15-Year Perspective for Pharmacogenomics Technology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Middle East 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 182: Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Middle East Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Middle East 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Iran 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 188: Iran Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Iran Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Iran 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Israel 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 194: Israel Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Israel Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Israel 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 200: Saudi Arabia Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Saudi Arabia Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Saudi Arabia 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: UAE 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 206: UAE Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: UAE Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: UAE 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 212: Rest of Middle East Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Rest of Middle East Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Rest of Middle East 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030
• AFRICA
  • Pharmacogenomics Technology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Pharmacogenomics Technology by Therapeutic Area - Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Africa 15-Year Perspective for Pharmacogenomics Technology by Therapeutic Area - Percentage Breakdown of Value Sales for Oncology, Neurological Disorders, Cardiovascular Disease, Immunological Disorders and Infectious Diseases for the Years 2015, 2025 & 2030
  • TABLE 218: Africa Recent Past, Current & Future Analysis for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Africa Historic Review for Pharmacogenomics Technology by Technology - Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Africa 15-Year Perspective for Pharmacogenomics Technology by Technology - Percentage Breakdown of Value Sales for Others, PCR, In-situ Hybridization, Immunohistochemistry and Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION